LON:SBTX - Skinbiotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 16.75 0.00 (0.00 %)
(As of 03/18/2019 04:00 PM ET)
Previous CloseGBX 16.75
Today's RangeGBX 16.51 - GBX 16.88
52-Week RangeGBX 8 - GBX 29.93
Volume56,869 shs
Average Volume261,826 shs
Market Capitalization£21.45 million
P/E Ratio-18.61
Dividend YieldN/A
BetaN/A
SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.

Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-4682760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 2.07 per share
Book ValueGBX 2.50 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£21.45 million
Next Earnings DateN/A
OptionableNot Optionable

Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions

What is Skinbiotherapeutics' stock symbol?

Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

Has Skinbiotherapeutics been receiving favorable news coverage?

Headlines about SBTX stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Skinbiotherapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Skinbiotherapeutics' key competitors?

What other stocks do shareholders of Skinbiotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Skinbiotherapeutics investors own include OptiBiotix Health (OPTI), Concepta (CPT), Avacta Group (AVCT), Big Sofa Technologies Group (BST), Namibian Resources (AAOG), Bahamas Petroleum (BPC), McEwen Mining (MUX), Nanoco Group (NANO), Gold Standard Ventures (GSV) and Teranga Gold (TGZ).

Who are Skinbiotherapeutics' key executives?

Skinbiotherapeutics' management team includes the folowing people:
  • Dr. Catherine O'Neill, CEO, Chief Scientific Officer & Director
  • Mr. Douglas John Quinn, CFO, Company Sec. & Director

How do I buy shares of Skinbiotherapeutics?

Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Skinbiotherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 16.75.

How big of a company is Skinbiotherapeutics?

Skinbiotherapeutics has a market capitalization of £21.45 million.

What is Skinbiotherapeutics' official website?

The official website for Skinbiotherapeutics is http://www.skinbiotherapeutics.com/.

How can I contact Skinbiotherapeutics?

Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.


MarketBeat Community Rating for Skinbiotherapeutics (LON SBTX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Skinbiotherapeutics and other stocks. Vote "Outperform" if you believe SBTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel